Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
1,201,989
-
Shares change
-
-699,747
-
Total reported value, excl. options
-
$70,984,650
-
Value change
-
-$41,248,475
-
Number of buys
-
20
-
Number of sells
-
-20
-
Price
-
$59.06
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q2 2017
54 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q2 2017.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,201,989 shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (350,062 shares), CITIGROUP INC (200,335 shares), UBS Group AG (105,938 shares), RAYMOND JAMES & ASSOCIATES (97,526 shares), MORGAN STANLEY (79,383 shares), BANK OF AMERICA CORP /DE/ (71,911 shares), Raymond James Financial Services Advisors, Inc. (48,612 shares), STUYVESANT CAPITAL MANAGEMENT (27,420 shares), CITADEL ADVISORS LLC (20,853 shares), and Psagot Investment House Ltd. (18,395 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.